In conclusion, EMP3 and CHI3L1 can be used as prognostic indicators in low-grade gliomas, and the OS and DFS of patients with low EMP3 and CHI3L1 are significantly better than those of patients with high EMP3 and CHI3L1. This evidence concerns the gene EMP3 and glioma.